GLP-1 is a hormone pathway and drug class. Tirzepatide is related but not a plain GLP-1-only drug. It activates both the GIP and GLP-1 receptors, which is why labels describe it as a GIP receptor and GLP-1 receptor agonist. The same active ingredient is sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea with obesity. It often produces larger average weight loss than semaglutide in trials, but it is not automatically the best or safest choice for every person.
Key takeaways
- Semaglutide is a GLP-1 receptor agonist; tirzepatide is a dual GIP/GLP-1 receptor agonist.
- Mounjaro and Zepbound are both tirzepatide, but they have different approved uses.
- Zepbound trial averages are high, but averages are not individual predictions.
- Side effects overlap heavily with GLP-1 drugs because tirzepatide still activates GLP-1 receptors.
- Coverage, contraindications and tolerability often decide the real-world choice.
What is the mechanism difference?
Semaglutide products such as Ozempic and Wegovy are GLP-1 receptor agonists. They activate the GLP-1 receptor, helping regulate appetite, glucose-dependent insulin release, glucagon and gastric emptying. Tirzepatide activates the GLP-1 receptor too, but it also activates the GIP receptor. GIP stands for glucose-dependent insulinotropic polypeptide, another incretin hormone pathway involved in glucose and energy regulation.
That dual mechanism is why tirzepatide sits in a slightly awkward naming space. In everyday search language, people call it a GLP-1. In precise medical language, it is a dual GIP/GLP-1 receptor agonist. Both statements can appear online, but the second is more accurate.
| Comparison point | GLP-1-only examples | Tirzepatide |
|---|---|---|
| Receptors | GLP-1 receptor | GIP and GLP-1 receptors |
| Common brands | Ozempic, Wegovy, Rybelsus, Saxenda | Mounjaro, Zepbound |
| Diabetes brand | Ozempic, Rybelsus, Trulicity, Victoza | Mounjaro |
| Weight brand | Wegovy, Saxenda | Zepbound |
| Side-effect pattern | Digestive symptoms are common | Digestive symptoms are also common |
How do approvals differ?
Mounjaro is the diabetes-branded tirzepatide product. Zepbound is the weight-management tirzepatide product, and it also has an approval for moderate-to-severe obstructive sleep apnea in adults with obesity. This matters because insurance coverage follows labels and plan rules. A drug being the same molecule does not mean every brand, dose or indication is covered the same way.
Semaglutide has a similar brand split: Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management and cardiovascular risk reduction in certain adults with established cardiovascular disease and overweight or obesity. Our semaglutide vs tirzepatide guide compares those molecules directly.
Is tirzepatide stronger?
In major clinical trials, tirzepatide generally produced larger average weight loss than semaglutide 2.4 mg. That is why Zepbound often sits near the top of weight-loss comparison tables. But there are important limits. Trial populations differ, doses differ, adherence differs, and individual response varies. A person who tolerates semaglutide well and gets coverage for Wegovy may do better in real life than a person who cannot access or tolerate tirzepatide.
For diabetes, tirzepatide also performed strongly in head-to-head studies against semaglutide in people with type 2 diabetes. Again, that does not mean everyone should switch. Diabetes treatment depends on blood sugar goals, kidney and heart history, other medications, side effects and coverage.
Does tirzepatide feel different?
Many side effects overlap because tirzepatide still activates the GLP-1 receptor. Zepbound and Mounjaro labels list common digestive reactions such as nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, burping and reflux. Some people tolerate tirzepatide better than semaglutide. Some tolerate it worse. A careful prescriber usually starts low and increases gradually to reduce side-effect risk.
How should you choose?
The practical choice is not "GLP-1 or tirzepatide" in the abstract. It is: which specific product is approved for your goal, safe for your history, affordable under your coverage, and tolerable enough to continue? Bring those four questions into the appointment. The strongest average is only useful if the medicine is appropriate and sustainable for you.
Frequently asked questions
Is tirzepatide a GLP-1?
It has GLP-1 activity, but the more precise term is dual GIP/GLP-1 receptor agonist.
Is Mounjaro the same as Zepbound?
They contain the same active ingredient, tirzepatide, but Mounjaro is the diabetes brand and Zepbound is the weight-management and sleep-apnea-with-obesity brand.
Is Zepbound better than Wegovy?
It produced larger average weight loss in major trials, but "better" depends on your medical history, side effects, access and clinician judgment.
Can I switch from semaglutide to tirzepatide?
Some people switch under clinician guidance. Do not try to convert doses yourself because the drugs are not dose-equivalent.